SCHEMBL2358889

SCHEMBL2358889

CCC(=O)c1ccc2c(c1)OC(F)(F)O2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 3/20 0.66
WNT3A P56704 3/20 0.66
ATM Q13315 1/20 0.57
SMYD3 Q9H7B4 3/20 0.47
HPGD P15428 2/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TAS2R8 Q9NYW2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2379710 0.83 CTNNB1 (0.66) CTNNB1WNT3AATMSMYD3HPGD
SCHEMBL11441068 0.82 CTNNB1 (0.64) CTNNB1WNT3ASMYD3HPGD
SCHEMBL15980036 0.81 CTNNB1 (0.76) CTNNB1WNT3ASMYD3HPGDTSHR
SCHEMBL13516290 0.81 CTNNB1 (0.56) CTNNB1WNT3AATMSMYD3MRGPRX4
SCHEMBL18641649 0.81 CTNNB1 (0.67) CTNNB1WNT3ASMYD3MRGPRX4MAPT
SCHEMBL1347343 0.81 CTNNB1 (0.58) CTNNB1WNT3ASMYD3MRGPRX4MAPT
SCHEMBL10407674 0.80 CTNNB1 (0.61) CTNNB1WNT3ASMYD3MRGPRX4MAPT
SCHEMBL23209151 0.80 CTNNB1 (0.61) CTNNB1WNT3AATMSMYD3HPGD
SCHEMBL15969201 0.80 CTNNB1 (1.00) CTNNB1WNT3ASMYD3MRGPRX4TSHR
SCHEMBL29214587 0.80 CTNNB1 (0.54) CTNNB1WNT3ASMYD3MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326749-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4536655-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF Sionna Therapeutics Inc. (US) 2025-04-16 EP disclosed
CN-119677730-A Compounds, compositions, and methods of use thereof 希安纳医疗公司 2025-03-21 CN disclosed
WO-2023240267-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2023-12-14 WO disclosed
WO-2023240267-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2023-12-14 WO disclosed
US-10017508-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-07-10 US disclosed
EP-2848618-B1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-03-14 EP disclosed
US-20170129887-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-05-11 US disclosed
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed
EP-2848618-A1 NITROGENATED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-03-18 EP disclosed
EP-2349966-A1 NEW ANALOGS OF POLYSPHORIN AND USES THEREOF FOR TREATING OR PREVENTING MALARIA Assistance Publique - Hôpitaux de Paris (FR) 2011-08-03 EP disclosed
EP-2177496-A1 New analogs of polysphorin and uses thereof for treating or preventing malaria Assistance Publique - Hopitaux de Paris (FR) 2010-04-21 EP disclosed
EP-2177496-A1 New analogs of polysphorin and uses thereof for treating or preventing malaria Assistance Publique - Hopitaux de Paris (FR) 2010-04-21 EP disclosed
WO-2010040730-A1 NEW ANALOGS OF POLYSPHORIN AND USES THEREOF FOR TREATING OR PREVENTING MALARIA ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) 2010-04-15 WO disclosed
EP-0424125-A2 Aralkylamine derivatives, preparation method thereof and fungicides containing the same UBE INDUSTRIES, LTD. (JP) 1991-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A CTNNB1 1484/4885WNT3A 3188/4885ATM 3251/4885
US-20250326749-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, SLC26A4, PKD2 CTNNB1 1966/4885WNT3A 1706/4885ATM 2116/4885
US-20170129887-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A CTNNB1 1484/4885WNT3A 3188/4885ATM 3251/4885
US-10017508-B2 Nitrogenated heterocyclic compound PDE2A, PDE5A, PDE3A CTNNB1 1484/4885WNT3A 3188/4885ATM 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.